Targeted genetic and viral therapy for advanced head and neck cancers

Pin I. Huang; Ju Fang Chang; David H. Kirn; Ta Chiang Liu

doi:10.1016/j.drudis.2009.03.008

Targeted genetic and viral therapy for advanced head and neck cancers

Pin I. Huang, Ju Fang Chang, David H. Kirn, Ta Chiang Liu

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Head and neck cancers usually present with advanced disease and novel therapies are urgently needed. Genetic therapy aims at restoring malfunctioned tumor suppressor gene(s) or introducing proapoptotic genes. Oncolytic virotherapeutics induce multiple cycles of cancer-specific virus replication, followed by oncolysis, virus spreading and infection of adjacent cancer cells. Oncolytic viruses can also be armed to express therapeutic transgene(s). Recent advances in preclinical and clinical studies are revealing the potential of both therapeutic classes for advanced head and neck cancers, including the approval of two products (Gendicine and H101) by a governmental agency. This review summarizes the available clinical data to date and discusses the challenges and future directions.

Original language	English
Pages (from-to)	570-578
Number of pages	9
Journal	Drug Discovery Today
Volume	14
Issue number	11-12
DOIs	https://doi.org/10.1016/j.drudis.2009.03.008
State	Published - Jun 2009

Access to Document

10.1016/j.drudis.2009.03.008

Cite this

@article{72695ac820e84830ab083aa0d861d357,

title = "Targeted genetic and viral therapy for advanced head and neck cancers",

abstract = "Head and neck cancers usually present with advanced disease and novel therapies are urgently needed. Genetic therapy aims at restoring malfunctioned tumor suppressor gene(s) or introducing proapoptotic genes. Oncolytic virotherapeutics induce multiple cycles of cancer-specific virus replication, followed by oncolysis, virus spreading and infection of adjacent cancer cells. Oncolytic viruses can also be armed to express therapeutic transgene(s). Recent advances in preclinical and clinical studies are revealing the potential of both therapeutic classes for advanced head and neck cancers, including the approval of two products (Gendicine and H101) by a governmental agency. This review summarizes the available clinical data to date and discusses the challenges and future directions.",

author = "Huang, {Pin I.} and Chang, {Ju Fang} and Kirn, {David H.} and Liu, {Ta Chiang}",

year = "2009",

month = jun,

doi = "10.1016/j.drudis.2009.03.008",

language = "English",

volume = "14",

pages = "570--578",

journal = "Drug Discovery Today",

issn = "1359-6446",

number = "11-12",

}

TY - JOUR

T1 - Targeted genetic and viral therapy for advanced head and neck cancers

AU - Huang, Pin I.

AU - Chang, Ju Fang

AU - Kirn, David H.

AU - Liu, Ta Chiang

PY - 2009/6

Y1 - 2009/6

N2 - Head and neck cancers usually present with advanced disease and novel therapies are urgently needed. Genetic therapy aims at restoring malfunctioned tumor suppressor gene(s) or introducing proapoptotic genes. Oncolytic virotherapeutics induce multiple cycles of cancer-specific virus replication, followed by oncolysis, virus spreading and infection of adjacent cancer cells. Oncolytic viruses can also be armed to express therapeutic transgene(s). Recent advances in preclinical and clinical studies are revealing the potential of both therapeutic classes for advanced head and neck cancers, including the approval of two products (Gendicine and H101) by a governmental agency. This review summarizes the available clinical data to date and discusses the challenges and future directions.

AB - Head and neck cancers usually present with advanced disease and novel therapies are urgently needed. Genetic therapy aims at restoring malfunctioned tumor suppressor gene(s) or introducing proapoptotic genes. Oncolytic virotherapeutics induce multiple cycles of cancer-specific virus replication, followed by oncolysis, virus spreading and infection of adjacent cancer cells. Oncolytic viruses can also be armed to express therapeutic transgene(s). Recent advances in preclinical and clinical studies are revealing the potential of both therapeutic classes for advanced head and neck cancers, including the approval of two products (Gendicine and H101) by a governmental agency. This review summarizes the available clinical data to date and discusses the challenges and future directions.

UR - http://www.scopus.com/inward/record.url?scp=67349252613&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2009.03.008

DO - 10.1016/j.drudis.2009.03.008

M3 - Review article

C2 - 19508919

AN - SCOPUS:67349252613

SN - 1359-6446

VL - 14

SP - 570

EP - 578

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 11-12

ER -

Targeted genetic and viral therapy for advanced head and neck cancers

Abstract

Access to Document

Other files and links

Fingerprint

Cite this